Cite
MLA Citation
A. Hansen et al.. “357 Toxicity remains the key determinant of recommended phase II dose (RP2D) of anticancer agents despite increasing use of non-toxicity endpoints.” European journal of cancer, vol. 51, n.d., pp. S73–. http://access.bl.uk/ark:/81055/vdc_100030628020.0x000060